[1. Jenwitheesuk E, Watitpun C, Vibhagool A, Chantratita W. Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002. Ann Clin Microbiol Antimicrob. 2003; 2:4.10.1186/1476-0711-2-4]Search in Google Scholar
[2. Sukasem C, Churdboonchart V, Sirisidthi K, Riengrojpitak S, Chasombat S, Watitpun C, et al. Genotypic resistance mutations in treatment-naive and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance. Jpn J Infect Dis. 2007; 60:284-9.]Search in Google Scholar
[3. Puthanakit T, Tangsathapornpong A, Ananworanich J, Wongsawat J, Suntrattiwong P, Wittawatmongkol O, et al. Thai national guidelines for the use of antiretroviral therapy in pediatric HIV infection in 2010. Asian Biomed. 2010; 4:505-13.10.2478/abm-2010-0065]Search in Google Scholar
[4. Sungkanuparph S, Techasathit W, Utaipiboon C, Chasombat S, Bhakeecheep S, Leechawengwong M, et al. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed. 2010; 4:515-28.10.2478/abm-2010-0066]Search in Google Scholar
[5. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999; 353:2195-9.10.1016/S0140-6736(98)12291-2]Search in Google Scholar
[6. Gallant JE. Antiretroviral drug resistance and resistance testing. Top HIV Med. 2005; 13:138-42.]Search in Google Scholar
[7. EuroGuidelines. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. . Aids. 2001; 15:309-20.10.1097/00002030-200102160-00003]Open DOISearch in Google Scholar
[8. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society- USA panel. Clin Infect Dis. 2008; 47:266-85.10.1086/589297]Open DOISearch in Google Scholar
[9. Hirsch MS, Richman DD. The role of genotypic resistance testing in selecting therapy for HIV. Jama. 2000; 284:1649-50.10.1001/jama.284.13.1649]Search in Google Scholar
[10. Bennett DE. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis. 2006; 19: 607-14.10.1097/QCO.0b013e3280109ff1]Open DOISearch in Google Scholar
[11. Chen JH, Wong KH, Chan K, Lam HY, Lee SS, Li P, et al. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping. J Clin Virol. 2007; 39:125-31.10.1016/j.jcv.2007.03.008]Open DOISearch in Google Scholar
[12. Lindstrom A, Albert J. A simple and sensitive ‘in-house’ method for determining genotypic drug resistance in HIV-1. J Virol Methods. 2003; 107:45-51.10.1016/S0166-0934(02)00188-X]Open DOISearch in Google Scholar
[13. Saravanan S, Vidya M, Balakrishnan P, Kumarasamy N, Solomon SS, Solomon S, et al. Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. J Virol Methods. 2009; 159:211-6.10.1016/j.jviromet.2009.03.021292321019490976]Search in Google Scholar
[14. Steegen K, Demecheleer E, De Cabooter N, Nges D, Temmerman M, Ndumbe P, et al. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods. 2006; 133:137-45.10.1016/j.jviromet.2005.11.00416375980]Search in Google Scholar
[15. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, Kaleebu P, et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods. 2010; 163:505-8.10.1016/j.jviromet.2009.11.011293296119917318]Search in Google Scholar
[16. Eshleman SH, Hackett J, Jr., Swanson P, Cunningham SP, Drews B, Brennan C, et al. Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol. 2004; 42:2711-7.10.1128/JCM.42.6.2711-2717.200442784415184457]Open DOISearch in Google Scholar
[17. Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, et al. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol. 2003; 41:1594-9.10.1128/JCM.41.4.1594-1599.200315385712682150]Open DOISearch in Google Scholar
[18. Beddows S, Galpin S, Kazmi SH, Ashraf A, Johargy A, Frater AJ, et al. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. J Med Virol. 2003; 70:337-42.10.1002/jmv.1040112766994]Open DOISearch in Google Scholar
[19. Fontaine E, Riva C, Peeters M, Schmit JC, Delaporte E, Van Laethem K, et al. Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J. J Acquir Immune Defic Syndr. 2001; 28:254-8.10.1097/00042560-200111010-0000811694832]Search in Google Scholar
[20. Jagodzinski LL, Cooley JD, Weber M, Michael NL. Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. J Clin Microbiol. 2003; 41:998-1003.10.1128/JCM.41.3.998-1003.200315029212624021]Open DOISearch in Google Scholar
[21. Mracna M, Becker-Pergola G, Dileanis J, Guay LA, Cunningham S, Jackson JB, et al. Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda. J Clin Microbiol. 2001; 39:4323-7.10.1128/JCM.39.12.4323-4327.20018854311724839]Open DOISearch in Google Scholar
[22. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother. 2003; 51:229-40.10.1093/jac/dkg07912562686]Search in Google Scholar
[23. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr. 2003; 33:336-42.10.1097/00126334-200307010-0000712843744]Search in Google Scholar
[24. Tovanabutra S, Beyrer C, Sakkhachornphop S, Razak MH, Ramos GL, Vongchak T, et al. The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002. AIDS Res Hum Retroviruses. 2004; 20:465-75.10.1089/08892220432308770515186520]Search in Google Scholar
[25. Yam WC, Chen JH, Wong KH, Chan K, Cheng VC, Lam HY, et al. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong. J Clin Virol. 2006; 35:454-7.10.1016/j.jcv.2005.10.01216386461]Open DOISearch in Google Scholar
[26. Fujisaki S, Fujisaki S, Ibe S, Asagi T, Itoh T, Yoshida S, et al. Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency virus type 1 in Japan. Jpn J Infect Dis. 2007; 60:113-7.]Search in Google Scholar
[27. Myint L, Ariyoshi K, Yan H, Frater AJ, Auwanit W, Pathipvanith P, et al. Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2002; 46:3861-8.10.1128/AAC.46.12.3861-3868.200213276712435689]Search in Google Scholar
[28. Sugiura W, Matsuda M, Abumi H, Yamada K, Taki M, Ishikawa M, et al. Prevalence of drug resistance-related mutations among HIV-1s in Japan. Jpn J Infect Dis. 1999; 52:21-2.10.7883/yoken.52.21]Search in Google Scholar
[29. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009; 17:138-45.]Search in Google Scholar
[30. Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 2010; 201:1303-7.10.1086/65161820350161]Search in Google Scholar
[31. Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods. 2009; 159:185-93.10.1016/j.jviromet.2009.03.016286314619490972]Search in Google Scholar